EUVIMEDEUVIMED entdecken
Crossref

Drug repurposing for pancreatic cancer: Lomitapide Mesylate as a potent HK2 inhibitor discovered via virtual screening

Xin Tan, Ying Zhang, Miao Liu, Fan Wang, Bangwei Huang, Dan Wang, Yue Wang, Jianguo Gao, Zijian Si, Xinyi Yang, Libo Liu, Zhaoshen Li und 2 weitere

Cellular Signalling · 2026-10 · 146 · 112634

DOI: 10.1016/j.cellsig.2026.112634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2026-10. Verfasst von Xin Tan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China; Shanghai Institute of Pancreatic Diseases, Shanghai, Ch…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Hexokinase, Drug Repositioning, Antineoplastic Agents. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Hebei Provincial Natural Science Foundation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer has an early diagnosis rate below 5% and is largely resistant to conventional chemotherapy. Aerobic glycolysis, a metabolic hallmark, drives Epithelial-Mesenchymal Transition (EMT) to promote tumor progression and drug resistance. Hexokinase 2 (HK2) is the rate-limiting enzyme that initiates glycolysis. It is specifically overexpressed in pancreatic cancer cells and is a potential therapeutic target. To identify HK2 inhibitors, we performed structure-based virtual screening of over 70,000 compounds. The top candidate, Lomitapide Mesylate (LM), was validated through molecular docking, molecular dynamics simulations, Drug Affinity Responsive Target Stability (DARTS), and Cellular Thermal Shift Assay (CETSA), confirming direct HK2 binding. In vitro, LM inhibited HK2 activity, exerting anti-proliferative and pro-apoptotic effects. In a mouse organoid-derived xenograft model, LM monotherapy suppressed tumor growth. Importantly, LM combined with gemcitabine significantly enhanced anti-tumor efficacy, indicating potential to reverse gemcitabine resistance. Mechanistically, this synergy was linked to LM-mediated reversal of HK2-driven EMT. Thus, LM inhibits HK2 to block EMT and synergize with gemcitabine, offering a novel therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsHexokinaseDrug RepositioningAntineoplastic AgentsHumansAnimalsCell Line, TumorMiceEpithelial-Mesenchymal TransitionMolecular Docking SimulationCell ProliferationDeoxycytidineGemcitabineApoptosisXenograft Model Antitumor AssaysMice, NudeMolecular Dynamics Simulation

Stichwörter der Autor:innen

Drug screeningGlycolysisHexokinase 2Lomitapide MesylatePancreatic cancer

Substanzen

HexokinaseHK2 protein, humanDeoxycytidineAntineoplastic AgentsGemcitabine

Autor:innen und Institutionen

  • Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China; Shanghai Institute of Pancreatic Diseases, Shanghai, China; National Key Laboratory of Immunology and Inflammation, Naval Med…
  • Department of Gastroenterology, No. 981 Hospital of the PLA, Chengde, Hebei, China.
  • Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China; Shanghai Institute of Pancreatic Diseases, Shanghai, China; Department of Gastroenterology, No. 981 Hospital of the PLA, Chen…

Förderung

  • Hebei Provincial Natural Science Foundation
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Tan, X., Zhang, Y., Liu, M., Wang, F., Huang, B., Wang, D., Wang, Y., Gao, J., Si, Z., Yang, X., Liu, L., Li, Z., Hu, L., & Wang, P. (2026). Drug repurposing for pancreatic cancer: Lomitapide Mesylate as a potent HK2 inhibitor discovered via virtual screening. Cellular Signalling, 146, 112634. https://doi.org/10.1016/j.cellsig.2026.112634

Vancouver

Tan X, Zhang Y, Liu M, Wang F, Huang B, Wang D, et al. Drug repurposing for pancreatic cancer: Lomitapide Mesylate as a potent HK2 inhibitor discovered via virtual screening. Cellular Signalling. 2026;146:112634. doi:10.1016/j.cellsig.2026.112634

BibTeX
@article{Tan2026,
  author = {Tan, Xin and Zhang, Ying and Liu, Miao and Wang, Fan and Huang, Bangwei and Wang, Dan and Wang, Yue and Gao, Jianguo and Si, Zijian and Yang, Xinyi and Liu, Libo and Li, Zhaoshen and Hu, Lianghao and Wang, Pengyuan},
  title = {Drug repurposing for pancreatic cancer: Lomitapide Mesylate as a potent HK2 inhibitor discovered via virtual screening},
  journal = {Cellular Signalling},
  year = {2026},
  volume = {146},
  pages = {112634},
  doi = {10.1016/j.cellsig.2026.112634}
}
Kostenlos starten →